157 related articles for article (PubMed ID: 32688207)
1. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
[TBL] [Abstract][Full Text] [Related]
2. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.
Bouchet S; Poulette S; Titier K; Moore N; Lassalle R; Abouelfath A; Italiano A; Chevreau C; Bompas E; Collard O; Duffaud F; Rios M; Cupissol D; Adenis A; Ray-Coquard I; Bouché O; Le Cesne A; Bui B; Blay JY; Molimard M
Eur J Cancer; 2016 Apr; 57():31-8. PubMed ID: 26851399
[TBL] [Abstract][Full Text] [Related]
3. Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.
Farag S; Verheijen RB; Martijn Kerst J; Cats A; Huitema AD; Steeghs N
Clin Pharmacokinet; 2017 Mar; 56(3):287-292. PubMed ID: 27435281
[TBL] [Abstract][Full Text] [Related]
4. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
Zuidema S; Desar IME; van Erp NP; Kievit W
Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
8. Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
Teranishi R; Takahashi T; Nishida T; Kurokawa Y; Nakajima K; Koh M; Nishigaki T; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Motoori M; Omori T; Hirota S; Hayashi Y; Takehara T; Eguchi H; Doki Y
Int J Clin Oncol; 2023 May; 28(5):680-687. PubMed ID: 36971916
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
10. Imatinib plasma levels in patients with gastrointestinal stromal tumour under routine clinical practice conditions.
Del Rosario García B; Morales Barrios JA; Jurado JC; Díaz RR; Viña Romero MM; Padrón IM; Nazco Casariego GJ; Nicolás FG
J Oncol Pharm Pract; 2023 Oct; 29(7):1613-1618. PubMed ID: 36482704
[TBL] [Abstract][Full Text] [Related]
11. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Joensuu H; Blay JY; Comandone A; Martin-Broto J; Fumagalli E; Grignani G; Del Muro XG; Adenis A; Valverde C; Pousa AL; Bouché O; Italiano A; Bauer S; Barone C; Weiss C; Crippa S; Camozzi M; Castellana R; Le Cesne A
Br J Cancer; 2017 Oct; 117(9):1278-1285. PubMed ID: 28850565
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.
Verschuur AC; Bajčiová V; Mascarenhas L; Khosravan R; Lin X; Ingrosso A; Janeway KA
Cancer Chemother Pharmacol; 2019 Jul; 84(1):41-50. PubMed ID: 31006038
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
Yang Z; Pan L; Liu S; Li F; Lv W; Shu Y; Dong P
Cancer Sci; 2018 Sep; 109(9):2792-2800. PubMed ID: 29957833
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST).
Den Hollander D; Van der Graaf WTA; Desar IME; Le Cesne A
Acta Oncol; 2019 Nov; 58(11):1648-1654. PubMed ID: 31345082
[No Abstract] [Full Text] [Related]
17. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
[TBL] [Abstract][Full Text] [Related]
18. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
[TBL] [Abstract][Full Text] [Related]
19. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
[TBL] [Abstract][Full Text] [Related]
20. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Milhem M; Deutsch JM
Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]